Skip to content

US · LIMN

Liminatus Pharma, Inc. Class A Common Stock

Sector
Healthcare · Biotechnology
Headquarters
Cerritos, CA 90703

Price · as of 2026-09-04

$3.71

Market cap 2.76M

Price history

Weekly OHLC price history for LIMN, USD per share
WeekOpenHighLowCloseVolume
Apr 28, 2025 – May 2, 2025$5.01$16.44$5.01$8.040
May 5, 2025 – May 9, 2025$7.60$7.99$5.50$7.450
May 12, 2025 – May 16, 2025$8.22$9.40$5.75$6.450
May 19, 2025 – May 23, 2025$6.59$6.71$5.03$5.560
May 26, 2025 – May 30, 2025$5.85$6.59$4.40$5.430
Jun 2, 2025 – Jun 6, 2025$5.30$25.00$4.55$24.220
Jun 9, 2025 – Jun 13, 2025$22.55$26.68$10.80$14.420
Jun 16, 2025 – Jun 20, 2025$14.42$16.13$11.73$14.430
Jun 23, 2025 – Jun 27, 2025$13.97$33.66$9.00$9.480
Jun 30, 2025 – Jul 3, 2025$11.00$12.90$8.74$9.020
Jul 7, 2025 – Jul 11, 2025$9.00$9.00$5.05$6.650
Jul 14, 2025 – Jul 18, 2025$6.55$6.90$5.25$5.420
Jul 21, 2025 – Jul 25, 2025$5.91$9.38$5.44$8.710
Jul 28, 2025 – Aug 1, 2025$8.72$8.89$5.85$5.930
Aug 4, 2025 – Aug 8, 2025$6.02$6.31$4.20$4.420
Aug 11, 2025 – Aug 15, 2025$4.42$4.85$3.70$4.000
Aug 18, 2025 – Aug 22, 2025$4.05$4.12$2.53$3.410
Aug 25, 2025 – Aug 29, 2025$3.21$3.60$2.61$2.710
Sep 1, 2025 – Sep 5, 2025$2.95$3.09$2.67$2.670
Sep 8, 2025 – Sep 12, 2025$2.60$2.60$1.82$2.000
Sep 15, 2025 – Sep 19, 2025$1.98$1.98$1.23$1.260
Sep 22, 2025 – Sep 26, 2025$1.15$1.74$1.12$1.450
Sep 29, 2025 – Oct 3, 2025$1.50$2.09$1.49$1.730
Oct 6, 2025 – Oct 10, 2025$1.76$1.77$1.36$1.410
Oct 13, 2025 – Oct 17, 2025$1.43$1.50$1.11$1.150
Oct 20, 2025 – Oct 24, 2025$1.16$1.39$1.11$1.240
Oct 27, 2025 – Oct 31, 2025$1.26$1.70$1.17$1.390
Nov 3, 2025 – Nov 7, 2025$1.40$1.40$1.13$1.170
Nov 10, 2025 – Nov 14, 2025$1.20$1.24$1.02$1.070
Nov 17, 2025 – Nov 21, 2025$1.07$1.30$0.61$0.720
Nov 24, 2025 – Nov 28, 2025$0.73$1.06$0.72$1.040
Dec 1, 2025 – Dec 5, 2025$1.07$1.07$0.71$0.840
Dec 8, 2025 – Dec 12, 2025$0.91$0.92$0.83$0.850
Dec 15, 2025 – Dec 19, 2025$0.87$0.88$0.76$0.790
Dec 22, 2025 – Dec 26, 2025$0.79$0.80$0.64$0.650
Dec 29, 2025 – Jan 2, 2026$0.63$0.68$0.61$0.640
Jan 5, 2026 – Jan 9, 2026$0.67$0.94$0.67$0.730
Jan 12, 2026 – Jan 16, 2026$0.77$0.83$0.74$0.770
Jan 19, 2026 – Jan 23, 2026$0.77$0.80$0.69$0.770
Jan 26, 2026 – Jan 30, 2026$0.77$0.77$0.54$0.550
Feb 2, 2026 – Feb 6, 2026$0.57$2.63$0.54$1.840
Feb 9, 2026 – Feb 13, 2026$1.99$2.83$0.35$0.380
Feb 16, 2026 – Feb 20, 2026$0.25$0.28$0.21$0.230
Feb 23, 2026 – Feb 27, 2026$0.23$0.27$0.22$0.250
Mar 2, 2026 – Mar 6, 2026$0.25$0.28$0.21$0.230
Mar 9, 2026 – Mar 13, 2026$0.24$0.27$0.23$0.230
Mar 16, 2026 – Mar 20, 2026$0.24$0.25$0.19$0.210
Mar 23, 2026 – Mar 27, 2026$0.21$0.22$0.18$0.190
Mar 30, 2026 – Apr 2, 2026$0.18$0.19$0.16$0.180
Apr 6, 2026 – Apr 10, 2026$0.19$0.21$0.18$0.190
Apr 13, 2026 – Apr 17, 2026$0.19$0.24$0.18$0.220
Apr 20, 2026 – Apr 24, 2026$0.21$0.23$0.19$0.200
Apr 27, 2026 – May 1, 2026$0.20$0.21$0.20$0.210
May 4, 2026 – May 8, 2026$0.20$0.23$0.20$0.200
May 11, 2026 – May 15, 2026$0.20$0.21$0.18$0.180
May 18, 2026 – May 22, 2026$0.19$0.36$0.13$0.170
May 25, 2026 – May 29, 2026$0.17$0.19$0.16$0.160
Jun 1, 2026 – Jun 5, 2026$0.17$0.21$0.14$0.140
Jun 8, 2026 – Jun 12, 2026$0.14$0.15$0.12$0.120
Jun 15, 2026 – Jun 18, 2026$0.12$0.13$0.11$0.120
Jun 22, 2026 – Jun 26, 2026$0.12$0.12$0.10$0.110
Jun 29, 2026 – Jul 2, 2026$0.11$0.21$0.10$0.140
Jul 6, 2026 – Jul 10, 2026$0.16$0.16$0.11$0.110
Jul 13, 2026 – Jul 17, 2026$0.11$0.20$0.10$0.120
Jul 20, 2026 – Jul 24, 2026$0.12$0.13$0.11$0.110
Jul 27, 2026 – Jul 31, 2026$0.11$5.50$0.10$5.150
Aug 3, 2026 – Aug 7, 2026$5.20$6.36$4.80$5.150
Aug 10, 2026 – Aug 14, 2026$5.03$9.20$4.99$7.000
Aug 17, 2026 – Aug 21, 2026$6.58$7.48$5.15$5.160
Aug 24, 2026 – Aug 28, 2026$5.03$5.04$4.23$4.230
Aug 31, 2026 – Sep 4, 2026$4.24$4.26$3.42$3.710

Valuation

MetricValueUpside
IC Value
P/E-0.54
P/B-0.56
P/S
EV/EBITDA-0.66
PEG-7.23
P/TBV-0.56

Valuation history

Annual price overlaid with each model's fair value. Y-axis is log scale.

Annual price and model valuations for LIMN, USD per share
YearPriceAIICGraham-DoddGraham Formula
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025$0.23

Historic valuation ratios

Pick a category, then toggle metrics to compare.

USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Liminatus Pharma, Inc. Class A Common Stock

        Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.

        CEO
        Chris Kim
        Employees
        1
        Beta
        0.74

        Peer comparison

        Same-industry comparables, ranked by market cap.

        Scroll horizontally for additional metrics. Ticker column stays fixed.

        Peer comparison for LIMN: basic info, valuation models, ratios, profitability, leverage, growth, cash flow, dividends, enterprise value, and Altman Z-score.
        Basic InfoIC ValuationCore ValuationProfitabilityLeverage & LiquidityGrowthCash FlowDividendsEnterprise ValueRisk
        TickerCompany NamePriceMarket CapValueUpsideP/EP/BP/SEV/EBITDAPEGP/TBVGross MarginOperating MarginNet MarginROEROICROADebt/EquityInterest CoverageCurrent RatioQuick RatioNet Debt/EBITDAEPS GrowthSales GrowthFCF GrowthFCF YieldOp Cash Flow RatioCash ROICDividend YieldDividend PayoutShareholder YieldEV/EBITEV/FCFEV/SalesAltman Z-Score
        LIMNLiminatus Pharma, Inc. Cl…$0.102.76M-0.54-0.56-0.66-7.23-0.560.00%0.00%0.00%79.48%29.29%-610.85%-0.15-13.750.050.03-0.117.50%221.15%-180.26%-0.9798.47%0.00%0.00%58.05%-2.24-0.67-147.83
        ATHEAlterity Therapeutics Lim…$4.4575.39M$11.05+148%-6.291.8014.06-2.461.8097.66%-267.96%-223.35%-43.23%-905.76%-37.23%0.0012.9812.622.26-63.46%35.32%-9.20%-14.98%-3.24-711.67%0.00%0.00%26.85%-2.47-3.146.615.97
        BTAIBioXcel Therapeutics, Inc…$0.9027.84M$10.67+1,083%-0.26-0.1928.33-1.89-0.1974.45%-7829.75%-10887.38%74.14%293.73%-167.91%-1.15-2.960.830.53-1.54-75.63%-71.67%-20.01%-316.74%-1.07336.66%0.00%0.00%0.00%-1.98-1.73154.88-26.29
        DYAIDyadic International, Inc…$1.0036.44M$13.93+1,293%-3.3720.1220.12-3.26-22.4420.12-88.25%-579.88%-597.63%-397.80%518.81%-74.11%4.11-15.672.682.29-0.0615.00%-64.74%43.46%-23.00%-1.55413.99%0.00%0.00%0.00%-3.15-3.9518.29-12.95
        EVAXEvaxion Biotech A/S$3.1019.58M$0.75-76%-3.531.603.63-1.621.60100.00%-122.66%-102.38%-100.48%-351.08%-37.81%0.44-10.545.855.702.21-87.65%125.12%-48.56%-24.38%-1.56-282.89%0.00%0.00%76.12%-1.25-1.741.54-4.72
        JSPRJasper Therapeutics, Inc.$0.7111.53M-0.315.630.055.630.00%0.00%0.00%-230.31%511.94%-131.06%0.302.622.170.37-19.22%22.19%-329.99%-5.85490.64%0.00%0.00%0.00%0.050.05-18.65
        SABSSAB Biotherapeutics, Inc.$3.9037.28M$0.65-83%6.040.53-0.630.530.00%0.00%0.00%14.96%-138.42%12.23%0.04-203.419.469.13-0.27-78.53%-100.00%31.99%-57.03%-4.19-129.25%0.00%0.00%0.40%0.210.231.05

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $3.71) − 1 = — (IC, example).